Remaxol
Non-interventional, Prospective Study of Safety and Efficiency of the Drug Remaxol® (NTFF POLYSAN Ltd., Russia) in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05789797/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 40–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 368 чел. во всех странах исследования.
- Центров в реестре: 5 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (12.2024) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)1–2
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 19 · невключение: 10
Критерии включения
- The study can include all patients who are scheduled, at a physician's discretion, to receive the therapy with the drug Remaxol®, solution for infusions, or Ademethionine, lyophilizate for solution for intravenous and intramuscular injection, according to the approved instruction for the medical use of the drug and established clinical practice of a healthcare facility, and who meet all the following criteria:
- Males and females aged from 40 to 70 years inclusive.
- Verified diagnosis of neoplasm (morphologically proven).
- Receiving the course polychemotherapy (PCT).
- PCT regimens with pronounced hepatotoxic effects, which use drugs from the following pharmacologic classes:
- Competitive antagonists (5-Fluorouracil, Methotrexate etc.);
- Alkylating agents (Cyclophosphamide, Oxaliplatin etc.);
- Antitumor antibiotics (Doxorubicin, Bleomycin etc.);
- Drugs influencing tubulin (Trabectedin, Paclitaxel etc.);
- Topoisomerase inhibitors (Irinotecan, Etoposide etc.).
- <!-- -->
- Contraindications for the continuation of PCT at the time of a visit to a physician for its continuation, because of developed hepatotoxicity.
- Stage of the treatment: supporting, hepatoprotective and detoxication therapy to correct hepatotoxicity developed during PCT, to remove it and continue the chemotherapeutic treatment.
- A patient is scheduled to receive one of the following infusion therapies with the following regimen, as part of the routine clinical practice:
- It is planned to administer the drug Remaxol®, solution for infusions, by intravenous drop infusion in the dose of 400 ml/day, on everyday basis for 12 days.
- It is planned to administer the drug Ademethionine, lyophilisate for solution for intravenous and intramuscular injection, by intravenous drop infusion in the dose of 800 mg/day, on everyday basis for 14 days. ECOG performance status score: 1-2 inclusive (Karnofsky score: 50-80 %).
- Hepatotoxicity grade according to the classification of the US National Cancer Institute (NCCN, CTC) - 2 and 3.
- Scores by selected parameters of CTCAE (National Cancer Institute Common Toxicity Criteria for Adverse Events) scale - I and II.
- Patient's written consent for participation in the study according to the current legislation.
Критерии невключения
- Pregnancy, breast-feeding.
- Mental disorders requiring psychiatric observation.
- Chronic alcohol abuse and/or substance abuse.
- HIV-infection, syphilis, virus hepatitis, autoimmune hepatitis, storage diseases, tuberculosis.
- Administration of monoclonal antibodies, (multi)kinase inhibitors during the PCT session immediately preceding this study.
- Administration of methionine-, Ademetionine-, malate- and/or succinate-containing medicines during the last month.
- Prescription of other malate-, succinate, or methionine-containing medicines (mexidol, cytoflavin, etc.).
- Decompensation of any severe/clinically apparent somatic diseases of the kidneys, liver, cardiovascular system, respiratory system, endocrine system, etc., as decided by the investigating physician.
- Contraindications mentioned in the approved instructions for use of medicines applied in the study (idiosyncrasy to the product components).
- Disease or use of medicines, which, in the doctor's opinion, can influence safety, tolerability and efficiency of the study medicines.
Источник: ClinicalTrials.gov, NCT05789797 · запись обновлена в реестре 13 августа 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 18
- Difference of average ALT values in both of the groups, between the two timepoints: Visit 3 vs. baseline at Visit 1 (before starting therapy with the study medicines). — Baseline, up to 15 days
- Difference of average ALP values in both of the groups, between the two timepoints: Visit 3 vs. baseline at Visit 1 (before starting therapy with the study medicines). — Baseline, up to 15 days
Цель исследования
Cancer has moved from the tenth place to the second one over the last 100 years, being inferior to only cardiovascular diseases in morbidity and mortality.
40 % of hepatitis cases in patients older than 40 years and 25 % of cases of fulminant hepatic failure (FHF) are caused by drug hepatic toxicity. Cases of acute drug-induced hepatitis (ADIH) make 15-20 % of patients with fulminant hepatitis in Western Europe.
Где проходит
5 центров в 3 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05789797 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.